Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer

May 13th 2025

Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.

Dr Graham on the Significance of the FDA Approval of Mirvetuximab Soravtansine in Ovarian Cancer

May 12th 2025

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer

May 12th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Dr Graham on Notable Ongoing Studies in Ovarian Cancer

May 9th 2025

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8th 2025

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer

May 8th 2025

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

May 1st 2025

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Dr Simpkins on the Predictive Utility of Cyclin E1 for Azenosertib Response in Ovarian Cancer

April 30th 2025

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.

FDA Grants Fast Track Designation to INX-315 in CCNE1-Amplified, Platinum-Resistant Ovarian Cancer

April 30th 2025

INX-315 has received FDA fast track designation for the treatment of patients with CCNE1-amplified, platinum-resistant or refractory ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Rina-S Displays Early Efficacy in Advanced Ovarian Cancer

April 25th 2025

Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.

Dr Cho on the Investigation of Niraparib/Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

April 22nd 2025

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer

April 18th 2025

Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer

April 15th 2025

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.